Radiation Oncology/Therapy

ASTRO vice chair highlights momentum for ROCR Act

By Amerigo Allegretto

Chris Corso, MD, PhD, from ASTRO discusses why the ROCR Act is needed to stabilize reimbursement for radiation oncologists in the U.S.

March 19, 2025

Consolidation reigns in radiation oncology

By Will Morton

Solo practices in radiation oncology dropped significantly between 2015 and 2023 while the number of large practices increased by more than half.

March 7, 2025

ASTRO: Shorter radiation course safe for breast reconstruction

By Amerigo Allegretto

Research presented at the ASTRO annual meeting shows that a shorter course of postmastectomy radiation combined with breast reconstruction is safe.

October 2, 2024

ASTRO: Timing key to adding immunotherapy to chemoradiation

By Amerigo Allegretto

Timing may be key when adding immunotherapy to chemoradiation for lung cancer treatment.

October 1, 2024

ASTRO: Black patients voice distrust in medical research

By Will Morton

Spiritual beliefs and a distrust of clinical research may partly explain why Black patients choose not to participate in cancer trials.

September 30, 2024

ASTRO: IMRT and proton therapy equally effective for prostate cancer

By Will Morton

Intensity-modulated radiation therapy (IMRT) and proton therapy offer equally high quality of life and tumor control for people with prostate cancer.

September 30, 2024

ASTRO: Lu-177 dotatate shows promise for treating meningioma patients

By Kate Madden Yee

A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers.

September 30, 2024

ASTRO: Brain cancer patients treated by radiation recoup cognitive function

By Kate Madden Yee

Patients with brain metastases who experience cognitive side effects after radiation therapy appear to eventually regain cognitive function.

September 30, 2024

Bone marrow disorders associated with SARs in Lutathera patients

By Will Morton

Pretreatment bone marrow disorders may predict which patients are at risk for severe adverse reactions (SARs) when treated with lutetium-177 DOTATATE.

July 15, 2024

The rise of theranostics: Part 5 -- Advice from center administrators

By Liz Carey

Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.

July 12, 2024

Risk factor for blood disorders identified in PRRT patients

By Will Morton

Researchers have identified a risk factor that may be involved in potentially fatal blood disorders in patients undergoing peptide receptor radionuclide therapy (PRRT).

July 12, 2024

ASTRO chair responds to proposed cuts in 2024 MPFS

By AuntMinnie.com staff writers

ASTRO has issued a statement from Jeff Michalski, MD, in response to continued reimbursement declines in the proposed 2025 MPFS.

July 11, 2024

Page 1 of 462

Next Page